Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 56
Inquire Before Buying

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

Cushing's disease is a condition which results from hypersecretion of adrenocorticotropic hormone (ACTH) due to pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), plethora, menstrual disorders and weight gain. Treatment includes radiation, chemotherapy, and use of certain hormone-inhibiting drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
Diurnal Group Plc
Ipsen SA
Novartis AG
Strongbridge Biopharma plc
Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing's Syndrome and Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIM-23B065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levoketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osilodrostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Silibinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
Featured News & Press Releases
Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases
Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014
Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014
Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial
Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation from EMA to Treat Cushing's Syndrome
Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing's Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Diurnal Group Plc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Sterile Injectables Market – Analysis By Molecule Type, Drug Type, Indication, Distribution Channel, By Region, By Country (2018 Edition): Forecast to 2023 -- Molecule Type (Biologic, Small Molecule), Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Metabolic, Musculoskeletal), Channel (Hospital Pharmacy, Retail Pharmacy, E-commerce)
    Published: 25-Jun-2018        Price: US 2400 Onwards        Pages: 240
    Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Sterile Injectables Market by Molecule Type (Biologic, Small Molecule),  Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Met......
  • Global Erythropoietin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Erythropoietin Market 2018, Forecast to 2023
    Published: 23-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • Global Burkitt Lymphoma Treatment Market Research Report 2018
    Published: 22-Jun-2018        Price: US 2900 Onwards        Pages: 96
    This report studies the global Burkitt Lymphoma Treatment market status and forecast, categorizes the global Burkitt Lymphoma Treatment market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Burkitt Lymphoma Treatment market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of duri......
  • Global Vegetable Capsules Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Vegetable Capsules Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global Sugar Sphere Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 131
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sugar Sphere Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 132
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global Tyrosinase Market Research Report 2018
    Published: 22-Jun-2018        Price: US 2900 Onwards        Pages: 95
    This report studies the global Tyrosinase market status and forecast, categorizes the global Tyrosinase market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Tyrosinase market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major manufactu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs